CANbridge Pharmaceuticals Inc. (1228.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
CANbridge Pharmaceuticals Inc.
Address
Suzhou Industrial Park, Building 21
Suzhou, BE
China
Phone
86 10 8414 8018
Sector
Healthcare
Industry
Biotechnology
Employees
41
First IPO Date
December 10, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Qun Xue | Founder, Chairman of the Board, Chief Executive Officer & Member of Strategic Advisory Board | 3.92M | 1970 |
| Chris Chen | Senior Vice President of Human Resources | 0 | N/A |
| Joe Shen | Chief Operating Officer | 0 | N/A |
| Lillian Zhang | Senior Director & Head of Finance Operations and Controller | 0 | N/A |
| Rebecca Zhang | Chief Regulatory Advisor | 0 | N/A |
| Will Wang | Executive Director of Production | 0 | N/A |
| Qian Ma | Vice President, Company Secretary & General Counsel | 0 | N/A |
| Jeff Kou | Head of Clinical Operations and Senior Director of R&D Strategy & Portfolio Management | 0 | N/A |
| Jason West | Head of Global Gene Therapy Research | 0 | N/A |
| Gerald F. Cox | Chief Development Strategist & Interim Chief Medical Officer | 0 | 1959 |
Description
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
